In the NCCN management guidelines 2023 v.3 [17], the absolute risk of breast cancer for RAD51C and RAD51D mutation carriers was revised form 15–40% to 20–40%, and management was also revised to include annual mammograms and consideration of breast MRI with contrast starting at age 40. Here, RAD51C is linked to breast cancer.